CAPR Capricor Therapeutics, Inc. Quarterly Revenue Growth

Capricor Therapeutics, Inc. (CAPR) - corporate logo

Anticipation of the registration application for the primary Duchenne muscular dystrophy drug is creating positive momentum, and GURU.Markets data informs this chart, where the QoQ revenue growth rate reaches 0.00. The business foundation of Capricor Therapeutics (CAPR) relies on a team of geneticists developing cell therapy and cost optimization through the outsourcing of production to third-party contractors.

Capricor (CAPR) - Quarterly Revenue Growth Rate from 07/04/2022 to 11/20/2026

Summary analytical data breakdowns for Capricor Therapeutics (CAPR)

- current quotes and average value forecast:
Summary company analysis:CAPR - Capricor
Manufactured products of Capricor

The resilience of Capricor Therapeutics (CAPR) is based on the synergy between highly qualified scientists and innovations in the field of cardiac cell therapy. By analyzing the quarterly growth of total revenue, an investor can see the real efficiency of commercializing these developments. This metric measures the rate of change in sales within the daily trend, excluding one-time anomalies to assess market conditions. The steady growth of this indicator confirms the fundamental value of the assets and justifies the fair value of the business.